TACE治疗原发性肝细胞癌合并门静脉癌栓疗效及影响因素

摘要

Objective To assess the therapeutic effect and influencing factors of TACE for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT).Methods Data of 685 patients with HCC and PVTT were retrospectively analyzed.There were 475 patients treated with TACE (TACE group) and 210 patients treated with supportive treatment (supportive treatment group).The survival time of two groups were observed and compared.The multivariate Cox regression analysis was used to analyze the prognostic factors.Results The median survival time of all 685 patients was 6.3 months.The median survival time of patients in TACE group and supportive treatment group was 7.1 months and 5.2 months,respectively (P=0.002).The 6-,12-and 24-month survival rates were 57.30％,27.30％ and 12.10％ in TACE group,and 37.90％,12.20％ and 3.10％ in supportive treatment group,respectively.Univariate analysis showed that the Child-Pugh classification,the diameter of lesion,gamma-glutamyl transferase level and type of PVTT might be significant prognostic factors for overall survival.Multivariate Cox proportional hazard model analysis showed the Child-Pugh classification and type of PVTT were independent prognostic factors for overall survival.Further analysis showed that the median survival time of patients with type Ⅰ or Ⅱ PVTT in TACE group was 7.8 months,and that in supportive treatment group was 5.5 months.There were statistical differences of 6-,12-and 24-month cumulative survival rate between the 2 groups (P =0.001).The median survival time of patients with type Ⅲ or Ⅳ PVTT in TACE group was 5.3 months,and that in supportive treatment group was 4.5 months.There was no statistical difference of the 6-,12-and 24-month cumulative survival rate between the 2 groups (P=0.662).Conclusion TACE is effective in the treatment of HCC with PVTT.The major influencing factors for survival time of patients with HCC and PVTT are Child-Pugh classification and type of PVTT.The effect of TACE for HCC patients with type Ⅲ or Ⅳ PVTT is unsatisfied.%目的 探讨TACE治疗原发性肝细胞肝癌(HCC)合并门静脉癌栓(PVTT)的疗效及影响因素.方法 回顾性分析685例HCC合并PVTT患者的资料,其中475例接受TACE治疗(TACE组),210例接受支持治疗(支持治疗组).比较2组患者生存时间,采用Cox模型回归分析影响患者预后的因素.结果 685例患者中位生存时间6.3个月,其中TACE组和支持治疗组中位生存时间分别为7.1个月、5.2个月(P=0.002).TACE组和支持治疗组患者6、12、24个月累计生存率分别为57.30％、27.30％、12.10％和37.90％、12.20％、3.10％.单因素分析显示,Child-Pugh分级、HCC病灶最大径、谷氨酰转肽酶水平、癌栓分型可能是影响患者预后的因素.多元Cox风险比例模型显示,Child-Pugh分级和癌栓分型是影响患者预后的独立因素.Ⅰ、Ⅱ型癌栓患者中,TACE组和支持治疗组中位生存时间分别为7.8个月、5.5个月,2组6、12、24个月累计生存率差异有统计学意义(P=0.001);Ⅲ、Ⅳ型癌栓患者中TACE治疗组和支持治疗组中位生存时间分别为5.3个月、4.5个月,2组6、12、24个月累计生存率差异无统计学意义(P=0.662).结论 对HCC合并PVTT患者行TACE治疗有效,影响患者预后的主要因素为Child-Pugh分级和癌栓分型;对Ⅲ、Ⅳ型癌栓患者TACE未见明显获益.